Clinical Trials Logo

Clinical Trial Summary

Despite the current available therapies for opioid-dependent patients, most patients relapse. This research project focuses on the development of a novel compound, cannabidiol, to modulate opioid craving in humans based on animal models showing its selective effectiveness to inhibit drug-seeking behavior. The development of a targeted treatment for opioid relapse would be of tremendous medical and public health value.


Clinical Trial Description

Opioid abuse is a significant global public health problem. Of the over million opiate-dependent subjects today, only less than a quarter of such individuals receive treatment. Pharmacotherapeutic approaches traditionally have targeted 5 opioid receptors since heroin and its metabolites bind with highest affinity to this receptor subtype. Although such treatment strategies have improved substance abuse outcomes, they do not effectively block opiate craving and thus are still associated with high rates of relapse. Using a strategy of indirectly regulating neural systems to modulate opioid-related behavior, our preclinical rodent studies consistently demonstrated that cannabidiol (CBD), a nonpsychoactive component of cannabis, specifically inhibited cue- induced heroin-seeking behavior. CBD's selective effect on drug-seeking behavior was pronounced after 24 hrs and endured even two weeks after the last drug administration following short-term CBD exposure. The fact that drug craving is generally triggered by exposure to conditioned cues suggests that CBD might be an effective treatment for heroin craving, specially given its protracted impact on behavior. CBD has already been shown in various clinical studies to be well tolerated with a wide safety margin in human subjects. CBD thus represents a strong candidate for the development as a potential therapeutic agent in humans for opioid craving and relapse prevention. It is the goal of this exploratory phase of the project to (1) determine the safety and basic pharmacokinetic characteristics of CBD when administered concomitantly with opiate in humans and (2) characterize the acute (24 hr) and short-term (3 days) effects of CBD administration on cue-induced craving in drug-abstinent heroin-dependent subjects using a random double blind design. This exploratory investigation together with ongoing complementary preclinical rodent studies has the potential to significantly impact the development of a novel agent for drug relapse prevention that is critical for ending the continued cycle of substance abuse. PUBLIC HEALTH RELEVANCE: Despite the current available therapies for opioid-dependent patients, most patients relapse. This research project focuses on the development of a novel compound, cannabidiol, to modulate opioid craving in humans based on animal models showing its selective effectiveness to inhibit drug-seeking behavior. The development of a targeted treatment for opioid relapse would be of tremendous medical and public health value. ;


Study Design

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Outcomes Assessor), Primary Purpose: Treatment


Related Conditions & MeSH terms


NCT number NCT01311778
Study type Interventional
Source Hurd,Yasmin, Ph.D.
Contact
Status Completed
Phase Phase 1
Start date February 2010
Completion date October 2011

See also
  Status Clinical Trial Phase
Completed NCT02539823 - Acute and Short-term Effects of CBD on Cue-induced Craving in Drug-abstinent Heroin-dependent Humans Phase 2
Recruiting NCT01934751 - Effectiveness of a Hospital Addiction Service in Treating Opioid and Alcohol Addiction N/A
Completed NCT00913770 - Models of Screening, Brief Intervention With a Facilitated Referral to Treatment (SBIRT) for Opioid Patients in the Emergency Department N/A
Completed NCT00929253 - Efficacy of Computer Delivered Community Reinforcement Approach (CRA) (Bup II) N/A
Terminated NCT02741076 - Discontinuation vs Continuation of Long-term Opioid Therapy in Suboptimal and Optimal Responders With Chronic Pain Phase 4
Completed NCT03015597 - Pilot Study of Contingency Management for Smoking Cessation N/A
Completed NCT02571400 - Prevalence and Predictors of Prolonged Post-surgical Opioid Use: a Prospective Observational Cohort Study N/A
Terminated NCT00552578 - Buprenorphine as a Treatment in Opiate Dependent Pain Patients Phase 4
Completed NCT00253890 - Insomnia and Drug Relapse Risk Phase 3
Completed NCT02667158 - A Survey to Eval the Relation Between Doctor/Pharmacy Shopping and Outcomes Suggestive of Misuse, Abuse and/or Diversion
Completed NCT02667210 - Study to Eval Relation Btw Doctor/Pharmacy Shopping & Outcomes of Misuse, Diversion, Abuse, Addiction by Med Rec Review
Active, not recruiting NCT01021566 - Opiate Detoxification Using the Combined Hemoperfusion-hemodialysis Phase 3
Withdrawn NCT01015066 - Comparison of Buprenorphine/Naloxone With Naltrexone in Opioid Dependent Adolescents Phase 4
Completed NCT02660619 - Validation of PRISM-5-Op, Measure Of Addiction To Prescription Opioid Medication
Active, not recruiting NCT02751762 - A Prospective Investigation of the Risks of Opioid Misuse, Abuse, and Addiction Among Patients Treated With Opioids for the Treatment of Chronic Pain
Completed NCT02657148 - Immediate Postpartum Nexplanon Placement in Opioid Dependent Women
Completed NCT02362256 - The Comparison of Stress Response to Rapid Opioid Detoxification Applying Different Methods of Opioid Antagonism N/A
Completed NCT01605539 - Acute and Short-term Effects of Cannabidiol Admin on Cue-induced Craving in Drug-abstinent Heroin Dependent Humans Phase 2
Completed NCT00204243 - Naltrexone Implants vs. MMT Among Inmates in the Norwegian Correctional Services Phase 2
Completed NCT02667262 - An Observational Study to Develop Algorithms for Identifying Opioid Abuse and Addiction Based on Admin Claims Data